Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, kkpennies, NewTrader2017
Search This Board: 
Last Post: 9/19/2017 6:20:03 PM - Followers: 121 - Board type: Free - Posts Today: 10
* shareholders, please consider purchasing product(s)


Awaiting Official Announcement of FDA Approval for FlutiCare

FlutiCare Approval could bring a BILLION DOLLARS in sales annually

REDONDO BEACH, CA--(Marketwired - Jul 12, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, discusses the potential impact of the anticipated FDA ruling on Innovus Pharmaceuticals' (OTCQB: INNV) ANDA filing for FlutiCare™, the company's over-the-counter treatment for allergic rhinitis.

FlutiCare™ is designed to treat non-allergic rhinitis -- better known as "hay fever" or "stuffy nose" -- which affects roughly 50 million Americans each year. While 70% of these individuals use over-the-counter products, more than half are not satisfied with the treatment option, according to an Asthma and Allergy Foundation of America survey, which suggests there's an opportunity for a prescription-strength OTC treatment option to capture market share from category leaders.

As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. The FDA decision is expected in the next several weeks.


The CEO has already signed an agreement for the manufacturing of FlutiCare

Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision

SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles.  Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.


Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. 
where he helped move the company's stock price from
19 Cents to $6.00 !!!
(Uplisted from OTC to NASDAQ)


Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.
President and Chief Executive Officer:

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.

Who are the major players at Innovus Pharma?


Share Structure:

Shares Outstanding:     150.5 Million (as of 4/28/17)   Dr. Damaj owns $23.7M shares.  Novalere owns 25.6M.  One person and One Entity own ~ 32.8% of the outstanding shares. 

Profitability expected exiting Q4 2017 !
- 2017 Projected Revenue of $15M (NOT counting FlutiCare), which would be approximately 3x GREATER than 2016. 


Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call

Corporate Presentation November 2016 (8-K  11/1/2016)

Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)

Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products

Major 2016 Accomplishments:



Where can INNV products be seen?


Existing Product Lines @ Innovus Pharma:

Newest Product:


PROSTAGORX™ is a clinical strength, multi response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in prevent prostate issues in the future. ProstaGorx™ was developed by top medical doctors and produced in a top-quality, cGMP certified and FDA registered laboratory environment under the most rigorously professional conditions. 

The positive benefits provided by the individual and combination ingredients in ProstaGorx™ have been published in leading medical journals.


Are you looking to boost your brain health?r

** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company

Cannabis Stocks News
Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
INNV News: Current Report Filing (8-k) 08/31/2017 06:11:33 AM
INNV News: Quarterly Report (10-q) 08/14/2017 04:43:27 PM
INNV News: Current Report Filing (8-k) 08/14/2017 04:35:16 PM
INNV News: Small Company Offering and Sale of Securities Without Registration (d) 08/02/2017 06:07:19 AM
INNV News: Statement of Changes in Beneficial Ownership (4) 07/03/2017 06:13:38 AM
#11037  Sticky Note Innovus Pharma Orders its First Commercial Batch of kkpennies 08/09/17 02:44:19 PM
#10696  Sticky Note $INNV Improving. We can handle it. Figure BooDog 07/21/17 05:45:08 AM
#11619   Someone bailed out midway through the sell off Clev3land 09/19/17 06:20:03 PM
#11618   Too bad (but not really) I was on BooDog 09/19/17 04:44:01 PM
#11617   Stay tuned. As I'm sure you will. BooDog 09/19/17 02:12:43 PM
#11615   Tell that to those clearing between 7 to BooDog 09/19/17 01:20:38 PM
#11614   Dead money for 6 months isn't funny to twistedfreak 09/19/17 01:16:11 PM
#11613   Funny! I'll still be here 2q 2018. eom. BooDog 09/19/17 01:10:23 PM
#11612   Vagaglide for the dry women of France. Vive twistedfreak 09/19/17 12:13:40 PM
#11611   over whelming market response from this fluff launch jbdiver 09/19/17 11:28:54 AM
#11610   Zestra launch announced. Think I was looking BooDog 09/19/17 10:29:10 AM
#11609   welcome to the .08's as INNV nears the twistedfreak 09/18/17 12:00:41 PM
#11608   It's fairly obvious that INNV will be a twistedfreak 09/16/17 10:06:27 PM
#11607   Yes, lack of patience usually does result in losses. BooDog 09/16/17 04:02:46 PM
#11606   Ok Shawn, it sounds like you have a gi197845 09/16/17 12:55:40 PM
#11605   I'm certainly not buying anymore. As far as ShawnP123 09/16/17 12:46:19 PM
#11604   Shawn, please sell your INNV shares now and gi197845 09/15/17 11:56:28 PM
#11600   I heard the same when I bought NOK healthywelth 09/15/17 07:18:56 PM
#11597   Well Yevvy, I think you're mistaken if you twistedfreak 09/15/17 04:58:15 PM
#11596   Redsox - what are you talking about healthywelth 09/15/17 04:44:30 PM
#11595   gi- better places to put your money. This ShawnP123 09/15/17 03:57:44 PM
#11594   Crashing and burning as we speak, time to gi197845 09/15/17 01:20:29 PM
#11593   It's amazing that after the conference, that INNV gi197845 09/15/17 01:05:51 PM
#11591   I think most of TF's comments have merit. ShawnP123 09/15/17 12:19:33 PM
#11590   redsox - nobody cares what are you healthywelth 09/15/17 10:41:44 AM
#11589   Dead money walking. IMO, there is little probability twistedfreak 09/15/17 06:54:48 AM
#11588   Well, you're personal friends with Damaj and golf gi197845 09/14/17 10:43:02 PM
#11587   Remember when the M.O.A.P was done and even gi197845 09/14/17 10:21:25 PM
#11586   Dr.Damaj will indicate that the hurricanes hurt sales gi197845 09/14/17 09:35:24 PM
#11585   I would be very surprised if Q3 revs ShawnP123 09/14/17 04:29:36 PM
#11584   I don't dismiss any potential negative when it ShawnP123 09/14/17 04:25:58 PM
#11583   Can you teach me how to short a stock? gi197845 09/14/17 10:37:59 AM
#11582   Innv isn't gonna make a run until it's Clev3land 09/13/17 07:19:41 PM
#11581   for your side , maybe . From my healthywelth 09/13/17 05:01:30 PM
#11580   Lol, overpaid by what, .0001 thousands of a gi197845 09/13/17 04:54:59 PM
#11579   You over paid. ShawnP123 09/13/17 02:24:44 PM
#11578   Got it 28K more shares early morning 0.1068c. healthywelth 09/12/17 11:48:54 AM
#11577   Big bid at .10. 200k interesting jbdiver 09/12/17 09:38:12 AM
#11576   The loss of life, property and well being gi197845 09/11/17 04:45:07 PM
#11575   redsox - Empty words like usually............keep dreaming. healthywelth 09/11/17 10:29:58 AM
#11574   Exactly. Expect .05 again by EOY if Damaj twistedfreak 09/11/17 08:16:45 AM
#11573   last time I bought at 5 cents biotech2 09/10/17 02:22:00 PM
#11572   I have 275,000 shares at around 11 cents. biotech2 09/10/17 02:19:25 PM
#11571   I have 100,000 at .1109 , I m NewTrader2017 09/09/17 07:16:03 PM
#11570   Good point article, but its not effect OTC healthywelth 09/09/17 05:15:34 PM
#11569   I have 126,850 shares @ 10cents. If smart COACH14 09/09/17 04:18:19 PM
#11568   I have 63,660 INNV shares @ an average gi197845 09/09/17 12:10:45 PM
#11567   I bought 4,356 more INNV shares at .10 gi197845 09/09/17 12:08:52 PM
#11566   Interesting article about the "Rule of 7" which gi197845 09/09/17 11:58:50 AM
#11565   Im a buyer below 12 cents. Will sell biotech2 09/09/17 10:49:14 AM
#11564   I'm still tracking INNV into mid 2018. Anyway, BooDog 09/08/17 04:24:54 PM
#11563   NT- Blaming the MM's and the buyers for ShawnP123 09/08/17 08:57:25 AM